Karim Chamie MD

Surgical Oncology

Professor, Urology, UCLA School of Medicine

UCLA Medical Center200 Medical Plaza, Suite 140Los Angeles, CA 90095
Phone+1 310-794-2858
Fax+1 310-794-2858

Dr. Chamie is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chamie's full profile Already have an account?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Urologic Surgical Oncology, 2011 - 2012
Ronald Reagan UCLA Medical CenterFellowship, Health Services Research, 2010 - 2011
UCLA School of Public HealthMSHS, Health Services Research, 2009 - 2010
University of California Davis HealthResidency, Urology, 2005 - 2009
University of California Davis HealthResidency, Surgery, 2003 - 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2004 - 2026
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Research Career Development Award STOP CANCER Research Foundation

Clinical Trials

Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
TERMINATED
EARLY_PHASE1
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
TERMINATED
PHASE2, PHASE3
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

Reply by Authors.
Sam S Chang, Karim Chamie, Charles A Seabury, Mark L Gonzalgo, Piyush Kumar Agarwal
The Journal of Urology. 2026-08-24
Reply by Authors.
Sam S Chang, Karim Chamie, Charles A Seabury, Mark L Gonzalgo, Piyush Kumar Agarwal
The Journal of Urology. 2026-08-20
Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG in BCG-Unresponsive NMIBC with Carcinoma In Situ ± Papillary Disease.
Sam S Chang, Karim Chamie, Charles A Seabury, Mark L Gonzalgo, Piyush Kumar Agarwal
The Journal of Urology. 2026-07-06

Journal Articles

Radical Prostatectomy Then and Now: Surgical Overtreatment of Prostate Cancer Is Declining from 2009 to 2016 at a Tertiary Referral Center
Amirali Salmasi, Izak Faiena, Karim Chamie, Urologic Oncology

Lectures

Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

Shorter Radiation Treatment After Surgery Found Safe for Prostate Cancer PatientsMay 14th, 2025
FDA Approval of Anktiva Heralds a New Era in the Treatment of BCG-Unresponsive Non–Muscle-Invasive Bladder CancerApril 23rd, 2024
How Bladder Cancer Immunostimulant N-803 May Shake Things UpApril 20th, 2023

Grant Support

Health Disparities in Prostate CancerNIH Loan Repayment Program2012–2016
Quality of Care in Patients with Bladder CancerAmerican Cancer Society2009–2011
Quality Of Care In Patients With Bladder Cancer.National Cancer Institute2009–2011